Koninklijke Philips N.V. $PHG Stock Holdings Increased by Blue Trust Inc.

Blue Trust Inc. lifted its stake in Koninklijke Philips N.V. (NYSE:PHG) by 30.0% in the second quarter, Holdings Channel.com reports. The firm owned 4,408 shares of the technology company’s stock after acquiring an additional 1,017 shares during the quarter. Blue Trust Inc.’s holdings in Koninklijke Philips were worth $106,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in PHG. Fiduciary Management Inc. WI increased its holdings in Koninklijke Philips by 21.7% in the first quarter. Fiduciary Management Inc. WI now owns 7,515,737 shares of the technology company’s stock worth $190,900,000 after buying an additional 1,339,055 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Koninklijke Philips by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company’s stock valued at $111,662,000 after purchasing an additional 106,044 shares during the last quarter. Timber Creek Capital Management LLC grew its holdings in Koninklijke Philips by 512.5% during the first quarter. Timber Creek Capital Management LLC now owns 105,185 shares of the technology company’s stock valued at $2,672,000 after purchasing an additional 88,012 shares during the last quarter. Northern Trust Corp grew its holdings in Koninklijke Philips by 5.1% during the first quarter. Northern Trust Corp now owns 1,690,402 shares of the technology company’s stock valued at $42,936,000 after purchasing an additional 81,653 shares during the last quarter. Finally, Aurora Private Wealth Inc. acquired a new position in Koninklijke Philips during the first quarter valued at approximately $1,695,000. Institutional investors and hedge funds own 13.67% of the company’s stock.

Koninklijke Philips Stock Up 1.9%

Koninklijke Philips stock opened at $28.33 on Friday. The company’s 50 day simple moving average is $27.66 and its 200 day simple moving average is $25.33. Koninklijke Philips N.V. has a fifty-two week low of $21.48 and a fifty-two week high of $32.25. The firm has a market capitalization of $27.28 billion, a price-to-earnings ratio of 149.11, a PEG ratio of 0.73 and a beta of 0.82. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.26 and a quick ratio of 0.81.

Koninklijke Philips (NYSE:PHG) last posted its earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.12. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $4.35 billion. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. As a group, sell-side analysts anticipate that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PHG. Weiss Ratings reissued a “sell (d+)” rating on shares of Koninklijke Philips in a research report on Wednesday, October 8th. Wall Street Zen cut Koninklijke Philips from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.